Conatus Pharmaceuticals (CNAT) Shares Pop Higher on Positive Zika Virus Mention

August 29, 2016 11:58 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Conatus Pharmaceuticals (NASDAQ: CNAT) shares pop higher amid positive WSJ mention regarding Zika virus.

UPDATE - The article notes Zika virus therapies recently published in the journal Nature Medicine.

Conatus has several patents for the liver-disease drug emricasan, which couldbe used as a potential treatment. Some of the patents don't expire until 2028.

Conatus is up 18 percent.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment